Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of central manifestations in patients with Niemann-Pick disease type C.

Genetics in medicine : official journal of the American College of Medical Genetics·2023
Same author

Insights into the genotype-phenotype relationship of ocular manifestations in Kabuki syndrome.

American journal of medical genetics. Part A·2023
Same author

A case of Aicardi syndrome associated with duplication event of Xp22 including <i>SHOX</i>.

Ophthalmic genetics·2023
Same author

Persistent Lactic Acidosis in an Infant With Milk Protein Allergy.

Clinical pediatrics·2022
Same author

From Genotype to Phenotype-A Review of Kabuki Syndrome.

Genes·2022
Same author

Targeting neurological abnormalities in lysosomal storage diseases.

Trends in pharmacological sciences·2021

Related Experiment Video

Updated: Feb 18, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.6K

Newborn Screening for Pompe Disease.

Olaf A Bodamer1, C Ronald Scott2, Roberto Giugliani3

  • 1Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts; olaf.bodamer@childrens.harvard.edu.

Pediatrics
|November 23, 2017
PubMed
Summary

Newborn screening (NBS) for Pompe disease is a promising public health initiative. However, inconsistent implementation across regions necessitates standardized approaches for effective early detection and treatment.

More Related Videos

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.5K
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

13.6K

Related Experiment Videos

Last Updated: Feb 18, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.6K
A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.5K
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

13.6K

Area of Science:

  • Public Health
  • Genetics
  • Pediatrics

Background:

  • Newborn screening (NBS) has significantly reduced morbidity and mortality for treatable conditions since its inception in 1963.
  • Pompe disease, a rare genetic disorder, is a suitable candidate for NBS due to the availability of presymptomatic treatments.
  • Current NBS programs for Pompe disease exhibit significant regional and global inconsistencies in implementation and scope.

Purpose of the Study:

  • To review current methodologies employed in newborn screening for Pompe disease.
  • To summarize the outcomes of ongoing and existing NBS programs for Pompe disease.
  • To discuss the challenges and potential limitations associated with Pompe disease NBS.

Main Methods:

  • Systematic review of established and emerging NBS technologies for Pompe disease.
  • Analysis of data from current and historical NBS programs in the US and internationally.
  • Expert consensus from the Pompe Disease Newborn Screening Working Group.

Main Results:

  • Pompe disease is identified as a viable condition for NBS, with varying degrees of program adoption globally.
  • Current NBS programs demonstrate the feasibility of early detection, but results are inconsistent.
  • Key challenges include assay variability, follow-up protocols, and resource allocation.

Conclusions:

  • Standardized NBS for Pompe disease is crucial for equitable access to early diagnosis and treatment.
  • Addressing implementation challenges is essential to maximize the public health benefits of Pompe disease NBS.
  • Further research and international collaboration are needed to optimize NBS strategies for Pompe disease.